MorphoSys (MOR) Stock Highlights

18.96 | +0%

2024-12-21 03:07:14

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the companys proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

Statistics

Range Today

18.96 18.96

Volume Today 0

Range 1 Year

4.18 19.5

Volume 1 Year 219.33M

Range 3 Year

3.17 19.5

Volume 3 Year 272.34M

Range 10 Year

3.17 37.96

Volume 10 Year 337.97M

Highlights

Market Capitalization 2.86B (mid)

Floating Shares 225.61K

Current Price 18.96

Price To Earnings -12.25

Price To Revenue 7.52

Earnings Per Share -1.5

Payout Ratio 0%

Performance

Latest 0%

1 Month +1.99%

3 Months +5.51%

6 Months +10.23%

1 Year +150.13%

3 Years +40.34%

5 Years -39.07%

10 Years -27.52%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.